newsfilter
← Latest News
GlobeNewswire·

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RNXT
  • RenovoRx announced the Japan Patent Office issued a Notice of Allowance for its first Japanese patent application (JP 2024-559262) titled "Method and Apparatus for Delivering an Agent Through the Vasa Vasorum."
  • The new patent protects the RenovoCath dual-occlusion catheter-based system equipped with integrated imaging & pressure-sensing technology for targeted drug delivery via the vasa vasorum.
  • This allowance strengthens RenovoRx's global intellectual property portfolio, which now includes 19 issued or allowed patents & 14 pending patents.
  • CEO Shaun Bagai stated the patent underscores advancements in targeted drug delivery to difficult-to-treat tumors while minimizing systemic drug exposure & side effects.
  • The patent supports RenovoRx's long-term commercial strategy in Japan by potentially facilitating partnerships, licensing discussions, & future commercialization efforts.
  • RenovoRx is actively commercializing RenovoCath in the US, generating approximately $1.1 million in sales during its first full year of commercial efforts.
  • The company is evaluating its novel drug-device combination candidate, intra-arterial gemcitabine delivered via RenovoCath (IAG), in the ongoing Phase III TIGeR-PaC trial.
  • IAG received Orphan Drug Designation for pancreatic cancer & bile duct cancer, providing seven years of market exclusivity upon FDA approval.
  • RenovoRx continues to seek revenue-generating activities, either independently or with a medical device commercial partner, to meet anticipated demand.